Log in to search using one of your social media accounts:

 

Nivolumab Approved for Liver Cancer Nivolumab Approved for Liver Cancer
The FDA has approved the immunotherapy for use in patients with hepatocellular carcinoma who have previously been treated with sorafenib.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology
PROVIDENCE, R.I., Sept. 25, 2017 -- (Healthcare Sales & Marketing Network) -- EpiVax, Inc., a leader in the fields of immunogenicity assessment, vaccine design, and immune-engineering today announced the launch of EpiVax Oncology Inc., a company focused o... Biopharmaceuticals, Personalized Medicine, Oncology EpiVax, EpiVax Oncology, epitopes, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 25, 2017 Category: Pharmaceuticals Source Type: news

Backed by Yale Cancer Center research, FDA approves new stomach cancer drug
A drug whose clinical testing was led by Dr. Charles Fuchs has become the first immunotherapy treatment for advanced stomach cancer. (Source: Yale Science and Health News)
Source: Yale Science and Health News - September 25, 2017 Category: Universities & Medical Training Source Type: news

TapImmune Appoints Peter Hoang as President and Chief Executive Officer
JACKSONVILLE, Fla., Sept. 25, 2017 -- (Healthcare Sales & Marketing Network) -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women's cancers, today announced that the... Biopharmaceuticals, Oncology, Personnel TapImmune, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 25, 2017 Category: Pharmaceuticals Source Type: news

Roche cancer immunotherapy Tecentriq wins EU approval
ZURICH (Reuters) - Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said. (Source: Reuters: Health)
Source: Reuters: Health - September 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

First Immunotherapy Approved for Gastric Cancer First Immunotherapy Approved for Gastric Cancer
Pembrolizumab is now indicated for third-line treatment of gastric or gastroesophageal junction cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 23, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors
AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - September 22, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Medical News Today: Multiple sclerosis: Novel gene immunotherapy could prevent, reverse disease
Using a new gene immunotherapy technique, researchers have reversed clinical symptoms of multiple sclerosis in mice, including paralysis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 22, 2017 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news

UK Backs Opdivo for Lung Cancer After Bristol-Myers Cuts Price UK Backs Opdivo for Lung Cancer After Bristol-Myers Cuts Price
Bristol-Myers Squibb's immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain's healthcare cost watchdog NICE after the drugmaker agreed a discounted price.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 21, 2017 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland Approval base... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, Pfizer, BAVENCIO, avelumab, Merkel cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2017 Category: Pharmaceuticals Source Type: news

Drug combination may improve impact of immunotherapy in head and neck cancer
(University of California - San Diego) Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy's effectiveness. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2017 Category: International Medicine & Public Health Source Type: news

A rapid alternative to standard safety tests for lentiviral vectors
(Cell Press) A new, publicly available test to assess the safety of cell therapy products altered by lentivirus generates results within a few hours, potentially hastening the pace at which viral immunotherapies move into clinical trial. Current assays required by the US Food and Drug Administration take about six weeks to complete. The rapid test, which does not have a significant risk of false positives, is also a fraction of the cost of the standard approach. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 21, 2017 Category: Cancer & Oncology Source Type: news

Parker Institute begins dosing in Phase Ib/II combination trial for pancreatic cancer
The Parker Institute for Cancer Immunotherapy and Cancer Research Institute in the US have started dosing patients in a Phase Ib/II clinical trial to investigate the combination of standard chemotherapy and immunotherapy for the treatment of pancreat … (Source: Drug Development Technology)
Source: Drug Development Technology - September 20, 2017 Category: Pharmaceuticals Source Type: news

NICE recommends Bristol-Myers Squibb ’s nivolumab for NSCLC patients on NHS
The UK National Institute for Health and Care Excellence (NICE) has recommended Bristol-Myers Squibb ’s immunotherapy drug Opdivo (nivolumab) for NHS use through the Cancer Drugs Fund (CDF) for the treatment of advanced non-small-cell lung cancer (NSC… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 20, 2017 Category: Pharmaceuticals Source Type: news

Behind the scenes at Juno ’s cancer immunotherapy manufacturing plant (Photos)
The Seattle-based biotech offered a rare look at the high-tech process behind its CAR-T immunotherapy cancer treatment. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - September 20, 2017 Category: Health Management Authors: Casey Coombs Source Type: news

Behind the scenes at Juno ’s cancer immunotherapy manufacturing plant (Photos)
The Seattle-based biotech offered a rare look at the high-tech process behind its CAR-T immunotherapy cancer treatment. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 20, 2017 Category: Biotechnology Authors: Casey Coombs Source Type: news

Starving cancer cells of oxygen could destroy tumours  
Israeli scientists showed the new immunotherapy treatment bolstered T cells - white blood cells with the specialised role of killing harmful cells. (Source: the Mail online | Health)
Source: the Mail online | Health - September 20, 2017 Category: Consumer Health News Source Type: news

Sean Parker's cancer-fighting institute aims 1st trial at tough target
Small Peninsula biotech company Apexigen and drug giant Bristol-Myers Squibb are teaming with the Parker Institute for Cancer Immunotherapy in an early-stage trial in metastatic pancreatic cancer patients. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - September 20, 2017 Category: Health Management Authors: Ron Leuty Source Type: news

AA Gill cancer drug available on the NHS at last
It is one of a revolutionary class of drugs called immunotherapy which work by teaching the body ’s immune system to fight cancer. But it was initially turned down by officials last year. (Source: the Mail online | Health)
Source: the Mail online | Health - September 20, 2017 Category: Consumer Health News Source Type: news

New clinical trial explores combining immunotherapy and radiation for sarcoma patients
(University of Maryland Medical Center) University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to destroy the main tumor as well as leftover microscopic cancer cells that may seed other tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

National Cancer Institute designates UCLA brain cancer program a site of research excellence
The brain cancer program at UCLA ’s Jonsson Comprehensive Cancer Center and the UCLA Brain Tumor Center has been designated a Specialized Program of Research Excellence, or SPORE, by the National Cancer Institute, making it one of only five brain cancer programs nationwide to receive this national recognition and substantial rese arch funding.The designation comes with an $11.4 million, five-year grant that recognizes UCLA ’s brain cancer program as one of the best in the country. The program supports research into the prevention, detection and treatment of one of the most lethal and deadly cancers, which often...
Source: UCLA Newsroom: Health Sciences - September 20, 2017 Category: Universities & Medical Training Source Type: news

UK backs Opdivo for lung cancer after Bristol-Myers cuts price
LONDON (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain's healthcare cost watchdog NICE after the drugmaker agreed a discounted price. (Source: Reuters: Health)
Source: Reuters: Health - September 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL
US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 19, 2017 Category: Pharmaceuticals Source Type: news

Mesothelioma Clinical Trials Involve Gene Therapy
Treatment options for malignant mesothelioma may soon include customized gene therapy, according to thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center in New York. Gene therapy involves a laboratory reprogramming of a patient’s own T cells, which are a type of white blood cell, to recognize and destroy the cancer. The U.S. Food and Drug Administration (FDA) recently approved the first gene therapy specifically for pediatric leukemia, signaling the start of a new approach to cancer treatment in this country. The newly approved treatment is also known as chimeric antigen rece...
Source: Asbestos and Mesothelioma News - September 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: CAR T cell therapy checkpoint blockade chimeric antigen receptor T cell therapy Dr. Andy Haas Dr. Prasad Adusumilli Dr. Scott Gottlieb FDA Commissioner gene therapy cancer gene therapy for mesothelioma immunotherapy clinical trial mali Source Type: news

Gates Foundation Invests $40 Million in UK Immunotherapy Company Gates Foundation Invests $40 Million in UK Immunotherapy Company
The Bill and Melinda Gates Foundation is to invest up to $40 million in privately held British biotech company Immunocore to support its development of immunotherapies for infectious diseases.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 19, 2017 Category: Allergy & Immunology Tags: Internal Medicine News Source Type: news

Futile: Prostate Cancer Vaccine Phase 3 Trial Ends Futile: Prostate Cancer Vaccine Phase 3 Trial Ends
Prostvac is an immunotherapy designed to induce T-cell responses and thus kill prostate cancer cells. As a monotherapy, it is not effective.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Papers of note in Science Translational Medicine 9 (407)
This week’s articles show that blocking a prometastatic process unintentionally impairs immunotherapy and report new therapeutic targets in type 2 diabetes and asthmatic lung disease. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - September 19, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

Inovio launches Phase I/IIa trial for MERS infection in South Korea
US-based immunotherapy firm Inovio Pharmaceuticals has launched a Phase I/IIa clinical trial of its vaccine candidate GLS-5300 to treat MERS (Middle East Respiratory Syndrome) infection in South Korea. (Source: Drug Development Technology)
Source: Drug Development Technology - September 18, 2017 Category: Pharmaceuticals Source Type: news

5T4-targeted Immunotherapy Promising in Metastatic Colorectal Cancer 5T4-targeted Immunotherapy Promising in Metastatic Colorectal Cancer
Immunotherapy with modified vaccinia Ankara-5T4 (MVA-5T4, TroVax) may improve survival in patients with metastatic colorectal cancer, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: Immunotherapy for lung cancer: What you need to know
What is immunotherapy for lung cancer and how does it work? Learn about the benefits, risks, and side effects. What is the future for immunotherapy? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 18, 2017 Category: Consumer Health News Tags: Lung Cancer Source Type: news

Altitude training for cancer-fighting cells
(Weizmann Institute of Science) Oxygen starvation could toughen up immune T cells for cancer immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 18, 2017 Category: Cancer & Oncology Source Type: news

Life- and Eye-Saving New Treatments for Uveal Melanoma Life- and Eye-Saving New Treatments for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 15, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Breakthrough Treatments Arriving for Uveal Melanoma Breakthrough Treatments Arriving for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Eye-Saving New Treatment Options for Uveal Melanoma Eye-Saving New Treatment Options for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 14, 2017 Category: Pathology Tags: Ophthalmology News Source Type: news

FDA OKs First'Biosimilar' Drug to Fight Cancer
New biologic could help drive down the cost of care, agency says Source: HealthDay Related MedlinePlus Pages: Cancer Immunotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 14, 2017 Category: Consumer Health News Source Type: news

Dogs' Immune Systems Are Much Like Ours And That's A Boon To Cancer Research
The recent success of immune-boosting cancer treatments like checkpoint inhibitors and CAR-T cells has intensified the demand for more immunotherapy innovations. Pet dogs could help in the effort. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 14, 2017 Category: Pharmaceuticals Authors: Arlene Weintraub, Contributor Source Type: news

Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take
Bristol-Myers Squibb will pay Halozyme $105 million for the right to use the smaller company's technology to develop easier-to-use versions of its best-selling cancer immunotherapy Opdivo, as well as as many as 11 other drugs in the larger company's research pipeline. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 14, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NYSE:BMY NASDAQ:HALO Source Type: news

Unintentional immunotherapy inhibition
(Source: ScienceNOW)
Source: ScienceNOW - September 14, 2017 Category: Science Authors: Pujanandez, L. Tags: twis Source Type: news

Medical News Today: New drug target found for 'most common cancer in infants'
Scientists have found a cell surface protein, which, when targeted using immunotherapy, successfully blocked neuroblastoma from spreading. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 13, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Immunotherapy treatment option for selected breast cancer patients, genetic study suggests
(Wellcome Trust Sanger Institute) Immunotherapy drugs could help some breast cancer patients based on the genetic changes in their tumors, researchers at the Wellcome Trust Sanger Institute and their collaborators find. Published today in Cancer Research, scientists identify particular genetic changes in a DNA repair mechanism in breast cancer. The results open up the possibility to another therapy option for around 1,000 breast cancer patients in the UK, who could benefit from existing drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 13, 2017 Category: Cancer & Oncology Source Type: news

Double agents: Vessels that help cancers spread can also boost immunotherapy
(Ecole Polytechnique F é d é rale de Lausanne) Scientists from Switzerland and the US have shown that lymphatic vessels can enable both metastasis and T-cell invasion, opening new paths for cancer immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 13, 2017 Category: Cancer & Oncology Source Type: news

FDA Extends Holds in Immunotherapy Trials in Blood Cancers FDA Extends Holds in Immunotherapy Trials in Blood Cancers
The Food and Drug Administration has slowed or fully halted more trials of immunotherapies in multiple myeloma and other blood cancersMedscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: Advanced melanoma: Groundbreaking trials could transform treatment
An immunotherapy and targeted therapy both promise to bring closer the day when melanoma is a disease that people live with instead of die from. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 12, 2017 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news

Clinical trials, radiation oncology research to be featured at ASTRO's Annual Meeting
(American Society for Radiation Oncology) The press program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO) will feature advances in cancer research, including reports from phase II and III clinical trials. Studies that examine innovative treatments, such as immunotherapy, mental health influences on cancer outcomes and optimal radiation dosing and sequencing, will also be presented at the largest meeting for the field of radiation oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

Best poster at ESMO 2017 shows positive trials twice as likely to be reported in lay press
(European Society for Medical Oncology) Randomized controlled trials with positive results are twice as likely to be reported by the lay press as those with negative trials, according to results from the Best Poster in Public Health and Health Economics at the ESMO 2017 Congress in Madrid. Trials on immunotherapy and targeted therapy were more commonly reported than those on chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

Immunotherapy Changes First-Line Paradigm in Advanced RCC Immunotherapy Changes First-Line Paradigm in Advanced RCC
For the first time, sunitinib has been beaten in a phase 3 trial; the combination of nivolumab and ipilimumab showed a significant improvement in overall survival.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cancer immunotherapy proves itself in earlier-stage disease
MADRID (Reuters) - Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body's defenses in the fight against tumors. (Source: Reuters: Health)
Source: Reuters: Health - September 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

KEYNOTE-040 evaluates pembrolizumab in head and neck cancer
(European Society for Medical Oncology) Immunotherapy with the checkpoint inhibitor pembrolizumab may be a better option than standard treatments for patients whose head and neck cancer has spread, or recurred after an initial round of chemotherapy, according to results of the Keynote-040 trial presented at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2017 Category: Cancer & Oncology Source Type: news

Modulating T-cell metabolism uncovers new technology for enhancing immunotherapy
(The Wistar Institute) T lymphocytes found in tumors and implicated in killing tumor cells cope with the shortage of oxygen and nutrients in the tumor microenvironment by using fat as the main source of energy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2017 Category: Cancer & Oncology Source Type: news

Cell surface protein may offer big target in treating high-risk childhood cancers
(Children's Hospital of Philadelphia) Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy -- harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2017 Category: Cancer & Oncology Source Type: news